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Abstract Phospholipase D (PLD) is known to stimulate cell
cycle progression and to transform murine ¢broblast cells into
tumorigenic forms, although the precise mechanisms are not
elucidated. In this report, we demonstrated that both PLD1
and PLD2 repressed expression of cyclin-dependent kinase in-
hibitor p21 gene in an additive manner. The phospholipase ac-
tivity of PLDs was important for the e¡ect. PLD1 repressed the
p21 promoter by decreasing the level of p53, whereas PLD2 via
a p53-independent pathway through modulating Sp1 activity.
Taken together, we suggest that PLD isozymes stimulate cell
growth by repressing expression of p21 gene, which may ulti-
mately lead to carcinogenesis.
+ 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Phospholipase D (PLD) catalyzes the hydrolysis of phos-
phatidylcholine to produce phosphatidic acid and choline [1].
The resulting phosphatidic acid is generally recognized as the
main signaling product of PLD and functions as an e¡ector in
multiple physiological processes. To date, two distinct iso-
forms of mammalian PLD have been cloned and character-
ized [2,3]. PLD1 has a low basal activity and is up-regulated
by small G proteins (ARF, Rho and Ral), protein kinase C
(PKC), and phosphatidylinositol 4,5-bisphosphate (PIP2) in
vitro. In contrast, PLD2 has a high basal activity, requires
PIP2, and is up-regulated by ARF and PKC [4,5]. The PLD
pathway is thought to play a critical role in regulating cell
responses that contribute to mitotic signaling and transforma-
tion [6^10]. Because of the important cellular functions of
PLD and its products, the enzymatic activity of PLD is tightly
regulated by a variety of hormones, growth factors, cytokines,
and other agonists involved in cellular signaling [11,12].
PLD activity is increased in response to treatment of mam-
malian cells with a variety of mitogenic signals. In addition, it
has been reported that PLD activity is signi¢cantly elevated in
human breast cancer [13], human renal cancer [14], human
gastric cancer tissue [15] and experimental colon cancer [16]
as well as in cells transformed by several transforming onco-
genes including v-Src [17], H-Ras [18], v-Raf [6] and v-Fps
[19]. PLD1 and PLD2 could cooperate with either c-Src or
epidermal growth factor receptor to transform rat ¢broblasts
[7,8]. Overexpression of either PLD1 or PLD2 inhibits expres-
sion of p21, which enables to overcome a cell cycle block
induced by high-intensity Raf signaling [18]. In addition, over-
expression of PLD isozymes transforms murine ¢broblast cells
into tumorigenic forms [9]. Taken together, these reports in-
dicate that the abnormally elevated PLD activity may cause
uncontrolled cell growth, which ultimately leads to carcino-
genesis. Despite these studies, the molecular mechanisms by
which PLD regulates cellular transformation are largely un-
known.
In this study, we investigated whether PLD isozymes mod-
ulate expression of p21, which is a universal inhibitor of cy-
clin-dependent kinase (CDK) and DNA replication that in-
duces cell cycle arrest at the G1-S checkpoint. In addition, we
analyzed the p21 promoter in detail to identify PLD-respon-
sive elements, which may provide a possible mechanism(s) by
which PLD modulates cell cycle control leading to cell growth
stimulation.
2. Materials and methods
2.1. Plasmids
PLD-expressing constructs containing cDNA for either PLD1 or
PLD2 in pcDNA3.1 (Invitrogen) were described previously [20,21].
pcDNA PLD1-K898R and pcDNA PLD2-K758R, encoding a cata-
lytic mutant of PLD isozyme 1 and 2, respectively, were also kindly
provided by Dr. Sung Ho Ryu (POSTECH, Pohang, Korea). Both
luciferase and CAT constructs containing a series of 5P deletion mu-
tants of the p21 promoter were described by Datto et al. [22] and El-
Deiry et al. [23], respectively. pTG13 that contains 13 copies of p53
binding site was described previously [24]. pGL2-2USp1 that contains
two copies of Sp1 binding site in pGL2-basic (Promega) was also
described previously [25].
2.2. Transfection and luciferase assay
HeLa and Hep3B cell lines used in this study were grown in Dul-
becco’s modi¢ed Eagle’s medium (DMEM) supplemented with 10%
fetal calf serum. Cells were seeded at 2U105 cells per 60 mm diameter
plate and transfected the next day with a calcium phosphate-DNA
precipitate containing target and e¡ect plasmid DNAs as previously
described [26]. Empty pcDNA3.1 vector was supplemented to equalize
the amount of DNA in the reaction mixture. To control the variation
for transfection e⁄ciency, 1 Wg of pCH110 (Pharmacia) containing the
Escherichia coli lacZ gene under the control of SV40 promoter was
cotransfected. After 48 h, the level of expression from the target was
analyzed by either CAT assay [26] or luciferase assay [27] depending
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on the reporter construct used and values obtained were normalized
to the L-galactosidase activity measured in the corresponding cell ex-
tracts.
2.3. Western blotting analysis
Cells were lysed in bu¡er (50 mM Tris^HCl, pH 8, 150 mM NaCl,
0.1% sodium dodecyl sulfate (SDS), 1% NP-40) supplemented with
protease inhibitors. Protein concentration of cell extracts was mea-
sured using the bovine serum albumin (BSA) protein assay kit (Bio-
Rad). 10 Wg of cell extracts was separated by SDS^polyacrylamide gel
electrophoresis (PAGE) and transferred onto a nitrocellulose mem-
brane (Hybond PVDF; Amersham). Western blotting was performed
with either anti-human p53 monoclonal antibody (Santa Cruz), anti-
human p21 rabbit polyclonal IgG (Santa Cruz), anti-human actin
monoclonal IgG (Santa Cruz) antibody, anti-human PLD rabbit poly-
clonal antibody and subsequently detected by chemiluminescent ECL
kit (Amersham) as recommended by the manufacturer. A polyclonal
antibody that recognizes both PLD1 and PLD2 was generated as
previously described [28].
3. Results
Recent studies have demonstrated that overexpression of
PLD isozymes stimulates cell growth and induces neoplastic
transformation of murine ¢broblast cells [9]. This phenome-
non might result from their repressive e¡ect on p21 expression
because p21 is a universal inhibitor of cyclin^CDK complexes
that induces cell cycle arrest at the G1-S checkpoint [29]. To
test this possibility, we determined whether expression of
PLD1 or PLD2 a¡ects the level of p21 protein. As shown
in Fig. 1, human cervical carcinoma HeLa cells transiently
transfected with either PLD1 (lane 2) or PLD2 (lane 3) clearly
showed the decrease of p21 protein level compared to the
control cells (lane 1) approximately 2- and 5-fold, respectively,
whereas the level of actin was not a¡ected by the expression
of PLDs. It is likely that the higher expression level of PLD2
compared to PLD1 might be responsible for the stronger re-
pression of p21 in PLD2-expressing cells. In addition, the level
of p53 protein was decreased up to 50% by expression of
PLD1 (Fig. 1, lane 2), suggesting that PLD1 might repress
the expression of p21 gene by down-regulating the level of
its upstream activator, p53. However, the p53 level was not
altered in the cells expressing PLD2 (Fig. 1, lane 3). Interest-
ingly, the catalytically inactive PLD1-K898R did not decrease
the protein level of p21 and p53 (Fig. 1, lane 4), indicating
that the phospholipase activity of PLD1 might be important
not only for the repression of p21 but also for the decrease of
p53.
Next, to examine whether PLD1 and PLD2 repress the
expression of p21 at the transcription initiation level, we in-
vestigated the e¡ects of PLD isozymes on the promoter activ-
ity of p21, using the p21 luciferase reporter (p21P) that con-
tains luciferase gene under the control of full-length p21
promoter [22]. Initially, p21P and PLD constructs were co-
transfected into HeLa cells and luciferase assay was per-
formed. Both PLD1 and PLD2 speci¢cally repressed the p21
promoter activity in a dose-dependent manner, up to approx-
imately 3- and 7-fold, respectively (Fig. 2a). To investigate
whether the phospholipase activity of PLD1 and PLD2 is
necessary for the repression of p21, we employed catalytically
inactive mutants, PLD1-K898R and PLD2-K758R. Both mu-
tants showed signi¢cantly impaired ability to repress the p21
promoter activity (Fig. 2b), indicating that the phospholipase
activity of PLD isozymes is responsible for the majority of the
e¡ect.
Next we investigated whether the repression of p21 pro-
moter by PLD1 and PLD2 requires decrease of p53 that is
an important activator for the p21 transcription. For this
purpose, p21P v2.3, which is driven by the truncation of
p21 promoter and thus is not responsive to p53 [22] was
tested. Consistently to the result of Western blot, luciferase
activity from p21P v2.3 was not signi¢cantly decreased by
PLD1 (Fig. 3a), suggesting that PLD1 might repress p21
gene through down-regulation of p53. In contrast, PLD2 re-
pressed the truncated promoter of p21P v2.3 approximately
6-fold. In addition, the e¡ect of PLD1 and PLD2 on the
promoter activity of p21 was additive (Fig. 3a). Taken togeth-
er, it is possible to speculate that PLD1 and PLD2 repress the
promoter activity of p21 through di¡erent pathways. To pro-
vide more discrete evidences for the di¡erence in p53 depen-
dency, the di¡erential roles of PLD1 and PLD2 were exam-
ined in human hepatocarcinoma Hep3B cells in which a
functional p53 protein is absent. Expression of PLD1 did
not repress the promoter activity of p21 in Hep3B cells
(Fig. 3b), con¢rming that PLD1, in contrast to PLD2, is de-
pendent on p53 for the repression of p21 gene. To further
demonstrate that the p21 promoter is repressed by PLD1
via a p53-dependent pathway, a luciferase construct pTG13
that contains 13 copies of p53 binding site [24] was employed.
As expected the luciferase activity was signi¢cantly repressed
by PLD1 but not by PLD2 (Fig. 3c). Based on the above
results, we conclude that PLD1 represses the p21 promoter
by down-regulating its upstream activator p53 whereas PLD2
does via a p53-independent pathway.
We next tried to determine regions of the p21 promoter
responsible for p53-independent repression by PLD2. To
this end, CAT and luciferase constructs containing a series
of 5P deletion mutants of the p21 promoter (Fig. 4a) were
employed. According to the CAT assay shown in Fig. 4b,
the activity from all constructs tested here (p21A to p21G)
was repressed by PLD2 although the repression fold was
slightly di¡erent. Therefore, the PLD2-responsive region
must be present at the downstream of 3246. Therefore, lucif-
 
 
 
 
 
 
Fig. 1. Repression of p21 gene expression by PLD isozymes. HeLa
cells were transfected with an empty vector (lane 1), PLD1- (lane
2), PLD2- (lane 3), or PLD1-K898R- (lane 4) expression plasmid
and the protein levels of p53, p21, PLD and actin were measured
by Western blotting.
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erase assay was performed using another series of p21 report-
er constructs [22]. As shown in Fig. 4c, deletion of the p21
promoter up to 393 did not reduce the e¡ect of PLD2. How-
ever, the minimal promoter of p21P smav1, which consists of
only 61 bp proximal to the transcriptional initiation site, was
not a¡ected by PLD2. In addition, internal deletion of the
sequence between 393 and 361 in p21P smav2 almost com-
pletely abolished the e¡ect of PLD2. Therefore, we deter-
mined the PLD2-responsive region between nucleotide posi-
tions 393 and 361.
To more precisely de¢ne the PLD2-responsive region in the
p21 promoter, ¢ve mutant constructs (93-S mut#1 to 93-S
mut#5), each containing 10 consecutive mutated bases be-
tween 393 and 344 in the promoter construct 93-S [22],
were examined (Fig. 5a). The promoter in 93-S mut#1 was
repressed by PLD2 in a similar manner to that of the 93-S.
However, the e¡ect was decreased in other mutant constructs
and almost completely lost in the case of 93-S mut#2. There-
fore, we conclude that the major PLD2-responsive element is
located between 384 and 375, based on the result with 93-S
mut#2. Interestingly, the PLD2-responsive element de¢ned
above is exactly overlapped with the TGF-L-responsive ele-
 
Fig. 2. Repression of p21 promoter by PLD1 and PLD2. a: Increasing amount of either pLD1 or pLD2 expression plasmid was cotransfected
with 5 Wg of the luciferase construct p21P [22] into HeLa cells and luciferase assay was performed. The empty reporter plasmid pGL2 was in-
cluded as a control. b: 5 Wg of p21P was cotransfected with 5 Wg each of plasmid expressing wild-type PLD1, PLD2, or their catalytically inac-
tive mutant forms into HeLa cells. Relative luciferase activities from p21 promoter in the absence or presence of PLD overexpression are indi-
cated by the solid bars and blank bars, respectively. Error bars indicate standard deviations obtained from three di¡erent experiments.
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ment (TLRE), which is known to mediate transcriptional ac-
tivation of the p21 gene by TGF-L [22] and a Sp1 binding site
(Sp1-1). Among them, the latter might be responsible for the
e¡ect because all other constructs that showed lower PLD2
responsiveness had at least one mutated Sp1 site. More direct
evidence that the Sp1 binding site is responsible for the e¡ect
by PLD2 was obtained with 93-S mut#2.3. This construct
contains a mutation of bases 376 and 377 from CT to
GG, thus maintains the consensus Sp1 binding site but
showed a signi¢cantly reduced ability to be activated by
TGF-L [22]. As the promoter activity of 93-S mut#2.3 was
successfully repressed by PLD2 (Fig. 5a), destruction of the
Sp1 site in 93-S mut#2 might be responsible for the loss of
PLD responsiveness.
To determine if the Sp1 binding site in the p21 promoter is
su⁄cient for the repression by PLD2, the site was used in an
attempt to confer PLD2 response to a heterologous promoter.
pGL2-2USp1 [25] in which two copies of Sp1 binding site
were inserted 5P of the TATA box was responsive to PLD2
(Fig. 5b). As the Sp1 binding site was su⁄cient to confer HBx
responsiveness to a previously non-responsive promoter, we
conclude that PLD2 represses the transcription of p21
through the Sp1 binding site, possibly by down-regulating
the activity of Sp1.
4. Discussion
Several reports suggest that the aberrant expression of PLD
is implicated in oncogenesis, although the exact mechanism is
not understood. Activation of PLD may result in the pro-
longed formation of diacylglycerol [30], and consequently
causes the long-term activation of PKC, which is necessary
for proliferation and tumorigenesis [31]. PLD activity has
been found to be markedly elevated in various cancer tissues
[13^17], cancer cell lines and transformed cells [6,17^19]. The
relationship between PLD and cancer is further supported by
the recent ¢ndings that some antitumor drugs act as inhibitors
of PLD [32]. In addition, overexpression of PLD enzymes
transforms murine ¢broblast into tumorigenic forms [9]. How-
ever, it is not understood how the elevated PLD activity leads
Fig. 3. p53-dependent repression of the p21 promoter by PLD1. a: Either PLD1- and/or PLD2-expression plasmid was cotransfected with lucif-
erase construct which transcription is driven by either a full-length (p21P; left panel) or a truncated form (p21P v2.3; right panel) of p21 pro-
moter into HeLa cells and luciferase assay was performed. b: p21P luciferase plasmid was cotransfected with either PLD1- and/or PLD2-ex-
pressing plasmid into p53-negative Hep3B cells and luciferase activity was measured. c: pTG13-luc that contains 13 copies of p53 binding site
in pT81-luc [24] was cotransfected with either an empty vector or PLD-expressing plasmid into HeLa cells. pT81-luc reporter plasmid that con-
tains a basic promoter element (TATA box) was included as a control.
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Fig. 4. Determination of PLD2-responsive elements in the p21 promoter. a: Schematic diagram of the various p21CAT [23] or p21 luciferase
[22] constructs used in this study. The p53 binding sites located at 32285 and 31394 are indicated by open boxes whereas TATA box in a
closed box. b: Full-length and truncated p21CAT constructs were cotransfected with either an empty vector or PLD2-expressing plasmid into
HeLa cells and CAT activity was measured. A quantitative estimate of chloramphenicol acetylation was obtained by excision of the substrate
and products from thin-layer chromatography plates, and subsequent measurement by liquid scintillation counting in an LKB 216 scintillation
counter. The relative chloramphenicol acetylation ratio was indicated as fold repression over control. c: Truncated forms of p21 promoter lucif-
erase constructs were cotransfected with either an empty vector or PLD2-expressing plasmid into HeLa cells and luciferase assay was per-
formed. The data are presented as fold repression over control.
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to cellular transformation. One possibility is that the increased
PLD activity causes cell cycle deregulation, which leads to
growth stimulation. Actually, overexpression of PLD iso-
zymes stimulates growth of murine ¢broblast cells [9]. Re-
cently, we have found that c-Src acts as a kinase of PLD
and PLD acts as an activator of c-Src. This transmodulation
between c-Src and PLD may contribute to the promotion of
cellular proliferation via ampli¢cation of mitogenic signaling
pathways [33].
Cell growth is regulated at several points in the cell cycle,
called checkpoints, at which the cycle can be arrested if pre-
vious events have not been completed. Among several check-
points, both extracellular and intracellular signals, which can
either promote or inhibit cell proliferation, tend to act by
regulating progression through a G1 checkpoint. Cell cycle
regulators critical for error-free execution of this event include
G1-Cdk composed of D-type cyclins (cyclins D1, D2 and D3)
and Cdk partners (Cdk4 and Cdk6) [34]. In addition, the
activities of G1 cyclin^cdk complexes are negatively regulated
by the binding of Cdk inhibitor proteins such as p21 and p27.
According to a previous report [9], overexpression of PLD1 or
PLD2 in mouse ¢broblast cells induces the expression of cy-
clin D3 protein, which may leads to the cell growth stimula-
tion by increasing G1 to S phase transition. In this study, we
demonstrated that PLD1 and PLD2 down-regulate the ex-
pression level of p21 through di¡erent mechanisms. PLD1
might repress it by decreasing the level of p53, which is an
important activator for the p21 transcription. The stability of
p53 might be decreased by PLD1, although transcriptional
repression of the p53 by PLD1 cannot be excluded. On the
other hand, PLD2 represses p21 expression through the Sp1
binding site located proximal to the TATA box. Therefore,
PLD2 might repress transcription of p21 by down-regulating
the activity of Sp1. Although PLD1 and PLD2 show di¡er-
ential repression of p21 gene, both PLD1 and PLD2 repress
p21 expression to stimulate cell cycle progression, which may
Fig. 5. Repression of the p21 promoter by PLD2 through Sp1 binding sites. a: 93-S mutant constructs [22], identical to the wild-type p21P 93-
S sequence with the exception of the sequences shown for each mutant construct were cotransfected with PLD2-expressing plasmid into HeLa
cells. The resulting luciferase activity was indicated as repression fold against the basal activity of the control. The positions of transcription
factor binding sites are underlined. b: pGL2-2USp1 [25] was cotransfected with either PLD1- or PLD2-expressing plasmid into HeLa cells. Re-
pression fold was calculated by dividing the luciferase activity by the basal activity obtained with the control vector.
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ultimately contribute to carcinogenesis. Therefore, this study
may provide a clue to explain oncogenic processes induced by
the elevated expression of PLD isozymes.
The phospholipase activity of PLD1 and PLD2 might be
important for the repression of p21 expression. However, the
catalytically inactive mutants of PLD1 and PLD2 still showed
a weak but signi¢cant level of repression activity. The residual
activity of PLD mutants might be due to their leaky enzyme
activities. Another possibility is that PLD might regulate ex-
pression of p21 via phospholipase activity-independent path-
ways. PLD may interact with p53 or other transcription fac-
tors involved in the regulation of p21 expression, either
directly or indirectly. Further studies are scheduled to identify
the domain of PLD responsible for the e¡ect. Elucidation of
the mechanism by which PLD1 destabilizes p53 might provide
several critical answers to understand the roles of PLD over-
expressed in several human cancers. In addition, the down-
regulation of Sp1 activity by PLD2 will be investigated in
detail.
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